Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2014

Roslin Cells Agrees to Manufacture Pfizer's Clinical Trial Product

  • Roslin Cells inked a contract with the Neusentis research unit of Pfizer to support the manufacture of retinal pigment epithelium cells to be used in a cell therapy clinical trial. The trial will evaluate the therapy for the treatment of patients suffering from age-related macular degeneration, the major cause of loss of vision in people aged 65 and older, as part of an ongoing collaboration with The London Project at the Institute of Ophthalmology, UCL.

    Manufacturing will take place in Roslin Cells’ GMP cellular therapy manufacturing facility in Edinburgh, which was licensed by the Medicines Healthcare Products Regulatory Agency in May 2013 for the manufacture of human cell therapy products for clinical trials.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »